Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tauroursodeoxycholic acid (TUDCA) for use in the treatment of neurodegenerative disorders

A tauroursodeoxycholic acid, neurodegenerative technology, applied in the direction of neurological diseases, sensory diseases, organic active ingredients, etc., can solve problems that have not been proved to be satisfactory

Inactive Publication Date: 2016-02-24
贝斯迪大药厂
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, this approach has not been proven satisfactory in arresting or significantly slowing the degenerative progression of ALS (8, 9)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tauroursodeoxycholic acid (TUDCA) for use in the treatment of neurodegenerative disorders
  • Tauroursodeoxycholic acid (TUDCA) for use in the treatment of neurodegenerative disorders
  • Tauroursodeoxycholic acid (TUDCA) for use in the treatment of neurodegenerative disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0025] Experimental part

[0026] This clinical study aimed to evaluate the disease-modifying effect of TUDCA in ALS patients when added to riluzole.

[0027] research population

[0028] Eligible patients were aged 18-75 years with clinically probable or confirmed ALS disease as defined by the revised El Escorial criteria (therevised El Escorialcriteria) (14), with less than 12 months of age at study entry course of disease. Patients were required to have a forced vital capacity (FVC) equal to or greater than 75% of predicted, to have been on a stable regimen with riluzole and vitamin E for at least 3 months, and to have evidence of disease progression during the past 3 months. These inclusion criteria were designed to recruit patients who were not severely disabled and whose disease progression could be effectively monitored.

[0029] Patients not eligible for this study are those who have previously undergone tracheostomy or cholecystectomy, those with evidence of moto...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

It is disclosed a method for the treatment of neurodegenerative disorders, such as ALS, Alzheimer's disease, Parkinson's disease, Huntington's disease and / or retinitis pigmentosa, which method comprises administering to a patient tauroursodeoxycholic acid or a pharmaceutically acceptable salt thereof.

Description

technical field [0001] The object of the present invention is the use of TUDCA or a pharmaceutically acceptable salt thereof in the treatment of neurodegenerative diseases such as ALS, Alzheimer's disease, Parkinson's disease, Huntington's disease and / or retinitis pigmentosa. The recipient of such treatment is preferably a human. Background technique [0002] Amyotrophic lateral sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative disorder characterized by loss of upper and lower motor neurons of the central nervous system (1). Degeneration of the lower motor neurons in the anterior horn of the spinal cord and brainstem leads to progressive muscular atrophy and eventually death from respiratory failure within a few years. Several complex biochemical and regulatory pathways may be involved in the pathogenesis of ALS (2). These different pathways interact with each other, ultimately leading to controlled cell death or apoptosis, which is thought to be a commo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/428A61K31/575A61K9/00A61P25/00A61P25/16A61P25/28
CPCA61K31/428A61K31/575A61P25/00A61P25/14A61P25/16A61P25/28A61P27/02A61K2300/00
Inventor G·里纳尔迪
Owner 贝斯迪大药厂
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com